A randomized, double-blind, multicenter study comparing MDX-010 [ipilimumab] monotherapy, MDX-010 in combination with a melanoma peptide vaccine [MDX 1379], and melanoma vaccine monotherapy in HLA-A2 0201-positive patients with previously treated unresectable stage III or IV melanoma.

Trial Profile

A randomized, double-blind, multicenter study comparing MDX-010 [ipilimumab] monotherapy, MDX-010 in combination with a melanoma peptide vaccine [MDX 1379], and melanoma vaccine monotherapy in HLA-A2 0201-positive patients with previously treated unresectable stage III or IV melanoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Ipilimumab (Primary) ; MDX 1379
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Oct 2017 Results of pooled data from three trial (CheckMate-067, CheckMate-037 and MDX010-20) assessing utility values across treatments and lines of treatment using data in advanced melanoma for two immuno-oncology agents, nivolumab and ipilimumab, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 10 Jun 2017 Biomarkers information updated
    • 13 May 2016 Results of comparison of overall survival data for ipilimumab, vemurafenib and dacarbazine from three trials including this published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top